IFEMA Madrid Exhibition Hall
Miltenyi Biotec booth 9
March 22–25, 2026 | Madrid, Spain
Never a more impactful meeting for us to attend than the 52nd Annual Meeting of the EBMT – this year held in Madrid, Spain!
An incredible event where we held our Satellite Symposium as well as many discussions on your approaches to graft engineering and CAR T cell manufacturing. If you were unable to attend the event, take a look below at the recordings, and make sure to get in contact to answer any further questions you may have. See you in 2027!
IFEMA Madrid Exhibition Hall
Miltenyi Biotec booth 9
March 22–25, 2026 | Exhibit Hall opening hours
Sunday, March 22, 9:00 a.m.–5:00 p.m.
Monday, March 23, 9:00 a.m.–5:00 p.m.
Tuesday, March 24, 9:00 a.m.–5:00 p.m.
Wednesday, March 25, 9:00 a.m.–1:00 p.m.
IFEMA Madrid
Room: Picasso
March 22, 2026
12:30 p.m.–2:00 p.m.
52nd Annual Meeting of the EBMT
March 22, 2026 | 12:30 p.m.–2:00 p.m.
12:30 p.m.
Welcome and introduction
Chair: José Antonio Pérez Simón, MD, PhD, Hospital Virgen del Rocío, Spain
12:40 p.m.
Haploidentical transplantation with TCRαβ-depleted graft and upfront memory T cell add-back in adults with haematological malignancies
Prof. Liang Piu Koh, National University Cancer Institute, Singapore
1:00 p.m.
Navigating graft-versus-leukemia and GvHD: adoptive infusion of T-allo10 after αβ T cell-depleted haploidentical HSCT
Alice Bertaina, MD, PhD, Stanford University, USA
1:20 p.m.
Beyond CD19: the potential of tandem CD19/CD22 CAR T cells in high-risk B-ALL
Antonio Pérez Martínez, MD, PhD, La Paz University Hospital, Spain
1:40 p.m.
CAR T cells for B cell-mediated autoimmune disease
Prof. Fabian Müller, MD, Uniklinikum Erlangen, Germany
Speaker: Prof. Liang Piu Koh, Senior Consultant, Department of Hematology-Oncology, National University Cancer Institute, Singapore
Mismatched related donor (haploidentical donor) hematopoietic stem cell transplantation (HSCT) offers an opportunity for nearly all patients to benefit from HSCT when an HLA genotypically matched sibling is unavailable. Early results with mismatched allografts were met with limited enthusiasm due to graft-versus-host disease (GVHD) and infectious complications, leading to unacceptable treatment-related morbidity and mortality. Recent advances – including effective T-cell depletion, the use of a 'megadose’ of stem cells, improved antimicrobial therapy, and reduced-intensity conditioning – have significantly lowered early transplant-related mortality and GVHD, while enabling robust and rapid engraftment. These improvements enhance the therapeutic potential of haploidentical transplantation. However, challenges such as delayed immune reconstitution causing post-transplant infectious complications and relapse remain, limiting the overall efficacy.
Over the past decade, various graft manipulation strategies have been developed, evolving from positive selection of CD34+ progenitor cells to depletion of CD3+ cells, and more recently, to selective depletion of TCRαβ+ and CD45RA+ naïve T cells. These innovative approaches have facilitated prompt hematopoietic engraftment, reduced GVHD, and enabled donor immune reconstitution through the adoptive transfer of donor’s TCRγδ+ T cells and other accessory cells.
Here, we share our local experience using this haplo-HSCT approach following depletion of TCRαβ+ and CD45RA+ naïve T cells for patients with high-risk hematological malignancies. Our results indicate that TCRαβ+-depleted haplo-HSCT eliminated severe GVHD and resulted in faster neutrophil recovery, with outcomes comparable to those achieved with HLA-matched sibling or unrelated donor transplants, along with the added benefits of lower cGVHD risk and improved GVHD-free/relapse-free survival.
Speaker: Alice Bertaina, MD, PhD, Lorry I. Lokey Professor of Pediatrics, Section Chief of Stem Cell Transplantation and Regenerative Medicine, and Co-Director of the Bass Center for Childhood Cancer and Blood Disease, Stanford University, USA
Allogeneic hematopoietic stem cell transplantation (HSCT) using TCRαβ+ T-cell/CD19+ B cell-depleted grafts enable transplantation across HLA barriers but remains limited by delayed immune reconstitution, infectious complications, and relapse. T-allo10 is a novel donor-derived cellular therapy enriched in alloantigen-specific type 1 regulatory T (Tr1) cells, designed to promote immune recovery while preserving graft-versus-leukemia activity without increasing graft-versus-host disease (GvHD).
We conducted a Phase I clinical study evaluating the safety, feasibility, and immunologic impact of T-allo10 administered following αβ-depleted haploidentical peripheral blood stem cell transplantation in pediatric and young adult patients with high-risk hematologic malignancies. Patients received T-allo10 at escalating dose levels after transplant. Key outcomes included safety, immune reconstitution, incidence of acute GvHD, relapse, and infectious complications. Correlative immune analyses were performed to assess immune dynamics and mechanisms of action.
T-allo10 was well tolerated with no dose-limiting toxicities observed. Transplant-related mortality was not observed during follow-up. Acute GvHD was limited to low-grade events and remained responsive to standard therapy, with no severe cases reported. Immune recovery was accelerated in a substantial proportion of treated patients compared with historical experience following αβ-depleted transplantation. Clinically meaningful reductions in viral reactivations were observed.
Immunologic analyses demonstrated rapid expansion and persistence of Tr1 cells following T-allo10 infusion, accompanied by early recovery of memory CD4+ T-cell populations. Favorable clinical outcomes were associated with an immunoregulatory profile characterized by attenuation of inflammatory signaling and enrichment of tolerance-associated pathways, supporting a mechanistic link between Tr1-mediated immune modulation, immune reconstitution, and disease control.
In summary, T-allo10 administered after αβ-depleted haploidentical HSCT is safe and associated with enhanced immune recovery, low rates of severe GvHD, and sustained disease control. These findings support αβ-depleted transplantation as a robust platform for adjunctive regulatory cell therapies and highlight T-allo10 as a promising strategy to improve transplant outcomes in high-risk pediatric and young adult patients.
Speaker: Antonio Pérez Martínez, MD, PhD, Head of Pediatric Hemato-Oncology and Hematopoietic Transplant Service, La Paz University Hospital, Spain
Relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) in children and young adults remains a major therapeutic challenge, particularly for patients with high-risk features. CD19-directed CAR T cell therapy has significantly improved outcomes; however, CD19-negative relapse and antigen escape limit its long-term efficacy. Dual-targeting strategies, such as tandem CD19/CD22 CAR T cells, aim to overcome these limitations by simultaneously targeting two critical B cell antigens. We report preliminary results from an ongoing study evaluating the safety and efficacy of tandem CD19/CD22 CAR T cells in pediatric and young adult patients with high-risk r/r B-ALL.
To date, 12 patients (mean age: 12 years; SD: 5.5) have been treated following lymphodepletion with fludarabine and cyclophosphamide. Nine patients (75%) had received prior CD19 CAR T cell therapy or multiple lines of chemotherapy. Manufacturing success was achieved in 100% of cases, with a median vein-to-vein time of 11 days. Early efficacy data is encouraging: overall response rate (ORR) was 90% at day 28, with 10 patients achieving MRD-negative complete remission. Seven of these patients were consolidated with hematopoietic stem cell transplantation (HSCT). Importantly, only one antigen-negative relapse (CD19 or CD22) has been observed to date. Cytokine release syndrome (CRS) occurred in 90% of patients (grade ≥3 in 30%), and immune effector cell-associated neurotoxicity syndrome (ICANS) was reported in 36% (all grade ≤2). One patient died due to pneumonia.
These preliminary findings suggest that tandem CD19/CD22 CAR T cell therapy is feasible, well tolerated, and may serve as an effective bridge to HSCT. Longer follow-up and expanded enrollment will clarify durability of response and inform integration into frontline or salvage settings. The REALLCART trial is ongoing (ClinicalTrials.gov identifier: NCT06709469, EudraCT 2023-509723-41-01).
Speaker: Prof. Fabian Müller, MD, Uniklinikum Erlangen, Erlangen, Germany
Chimeric antigen receptor (CAR) T cells specific for CD19 or B cell maturation antigen (BCMA) are now the standard treatment for relapsed/refractory B cell neoplasms. Because autoreactive B cells play a key role in the pathogenesis of autoimmune diseases (AID), it has been hypothesized that B cell-specific CAR T cells eliminate autoreactive B cell clones via a deep depletion of B cells and lead to a reset of the immune system.
In the past few years, CD19- and BCMA-based CAR T cell therapies have been applied to various B cell-mediated rheumatologic AIDs such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc) or idiopathic inflammatory myositis (IIM). B cell-specific CAR T cell treatment was able to induce deep and sustained remission and lead to clinical improvement of organ damage. Initial successes have also been recorded in other hematologic, neurologic, and gastroenterologic B cell-mediated AIDs.
The use of CAR T cell treatment in severe forms of chronic non-malignant diseases represents a novelty in medicine and opens up groundbreaking new possibilities and concepts for treatment.
Interested in connecting to learn more? Feel free to get in touch.
Kirsten Langeveld
Global Product Manager, Graft Engineering
You have previously chosen International as your location.
What do you want to do?